Can glucagon-like peptide-1 receptor agonists induce asthma? An analysis of the FAERS database

References

• Drucker DJ. Mechanisms of action and therapeutic ­application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001.
   PubMed Web of Science ®Google Scholar
• Strain WD, Smith C. Cardiovascular outcome studies in diabetes: how do we make sense of these new data? Diabetes Ther. 2016;7(2):175–185. doi:10.1007/s13300-016-0165-z.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. GIP and GLP-1: stepsiblings rather than monozygotic twins within the incretin family. Diabetes. 2019;68(5):897–900. doi:10.2337/dbi19-0005.
   PubMed Web of Science ®Google Scholar
• Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(3):737–745. doi:10.1210/jc.2010-2435.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ. The incretin effect in healthy ­individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016;4(6):525–536. doi:10.1016/S2213-8587(15)00482-9.
   PubMed Web of Science ®Google Scholar
• Holst JJ, Vilsbøll T, Deacon CF. The incretin system and its role in type 2 diabetes mellitus. Mol Cell Endocrinol. 2009;297(1–2):127–136. doi:10.1016/j.mce.2008.08.012.
   PubMed Web of Science ®Google Scholar
• Qiu M, Ding LL, Zhan ZL, Liu SY. Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors. Endocrine. 2021;73(1):31–36. doi:10.1007/s12020-021-02644-x.
   PubMed Web of Science ®Google Scholar
• Kanwar MK, Sunku R, Alruwaili F, Mufti MA, Raji M. Beneficial effects of glucagon-like peptide-1 ­receptor agonists in patients with asthma: a literature review. Cureus. 2022;14(10):e30812. doi:10.7759/cureus.30812.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, Matera MG. Glucagon-like peptide-1 ­receptor: a novel pharmacological target for treating human bronchial hyperresponsiveness. Am J Respir Cell Mol Biol. 2016;55(6):804–814. doi:10.1165/rcmb.2015-0311OC.
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–2157. doi:10.1053/j.gastro.2007.03.054.
   PubMed Web of Science ®Google Scholar
• Wu AY, Peebles RS. The GLP-1 receptor in airway ­inflammation in asthma: a promising novel target? Expert Rev Clin Immunol. 2021;17(10):1053–1057. doi:10.1080/1744666X.2021.1971973.
   PubMed Web of Science ®Google Scholar
• Batty MJ, Chabrier G, Sheridan A, Gage MC. Metabolic hormones modulate macrophage inflammatory ­responses. Cancers (Basel). 2021;13(18):4661. doi:10.3390/cancers13184661.
   PubMed Web of Science ®Google Scholar
• Bułdak Ł, Machnik G, Bułdak RJ, Łabuzek K, Bołdys A, Belowski D, Basiak M, Okopień B. Exenatide (a GLP-1 agonist) expresses anti-inflammatory properties in cultured human monocytes/macrophages in a protein kinase A and B/Akt manner. Pharmacol Rep. 2016;68(2):329–337. doi:10.1016/j.pharep.2015.10.008.
   PubMed Web of Science ®Google Scholar
• Wiegman CH, Michaeloudes C, Haji G, Narang P, Clarke CJ, Russell KE, Bao W, Pavlidis S, Barnes PJ, Kanerva J, et al. Oxidative stress–induced mitochondrial dysfunction drives inflammation and airway smooth muscle remodeling in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2015;136(3):769–780. doi:10.1016/j.jaci.2015.01.046.
   PubMed Web of Science ®Google Scholar
• Chen J, Mei A, Liu X, et al. Glucagon-like peptide-1 receptor regulates macrophage migration in monosodium urate-induced peritoneal inflammation. Front Immunol. 2022;13:90.
   Web of Science ®Google Scholar
• Guo C, Huang T, Chen A, Chen X, Wang L, Shen F, Gu X. Glucagon-like peptide 1 improves insulin ­resistance in vitro through anti-inflammation of macrophages. Braz J Med Biol Res. 2016;49(12):e5826. doi:10.1590/1414-431X20165826.
   PubMed Web of Science ®Google Scholar
• Mitchell PD, Salter BM, Oliveria JP, El-Gammal A, Tworek D, Smith SG, Sehmi R, Gauvreau GM, Butler M, O’Byrne PM, et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation. Clin Exp Allergy. 2017;47(3):331–338. doi:10.1111/cea.12860.
   PubMed Web of Science ®Google Scholar
• Ciepiela O, Ostafin M, Demkow U. Neutrophils in asthma–a review. Respir Physiol Neurobiol. 2015;209:13–16. doi:10.1016/j.resp.2014.12.004.
   PubMed Web of Science ®Google Scholar
• Chen J, Mei A, Wei Y, Li C, Qian H, Min X, Yang H, Dong L, Rao X, Zhong J, et al. GLP-1 receptor agonist as a modulator of innate immunity. Front Immunol. 2022;13:997578. doi:10.3389/fimmu.2022.997578.
   PubMed Web of Science ®Google Scholar
• Oh YS, Jun HS. Effects of glucagon-like peptide-1 on oxidative stress and Nrf2 signaling. Int J Mol Sci. 2017;19(1):26. doi:10.3390/ijms19010026.
   PubMed Web of Science ®Google Scholar
• Rogliani P, Matera MG, Calzetta L, Hanania NA, Page C, Rossi I, Andreadi A, Galli A, Coppola A, Cazzola M, et al. Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic ­patients. Respir Med. 2019;154:86–92. doi:10.1016/j.rmed.2019.06.015.
   PubMed Web of Science ®Google Scholar
• Foer D, Beeler PE, Cui J, Karlson EW, Bates DW, Cahill KN. Asthma exacerbations in patients with type 2 diabetes and asthma on glucagon-like peptide-1 ­receptor agonists. Am J Respir Crit Care Med. 2021;203(7):831–840. doi:10.1164/rccm.202004-0993OC.
   PubMed Web of Science ®Google Scholar
• Wang A, Tang H, Zhang N, Feng X. Association ­between novel glucose-lowering drugs and risk of asthma: a network meta-analysis of cardiorenal outcome trials. Diabetes Res Clin Pract. 2022;183:109080. doi:10.1016/j.diabres.2021.109080.
   PubMed Web of Science ®Google Scholar
• Steveling EH, Winzeler B, Bircher AJ. Systemic allergic reaction to the GLP-1 receptor agonist exenatide. J Pharm Technol. 2014;30(5):182–186. doi:10.1177/8755122514539462.
   PubMedGoogle Scholar
• Pradhan R, Patorno E, Tesfaye H, Schneeweiss S, Yin H, Franklin J, Pawar A, Santella C, Yu OHY, Renoux C, et al. Glucagon-like peptide-1 receptor agonists and risk of anaphylactic reaction among patients with type 2 diabetes: a multisite population-based cohort study. Am J Epidemiol. 2022;191(8):1352–1367. doi:10.1093/aje/kwac021.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA adverse event reporting system (FAERS) public dashboard. 2024. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.
   Google Scholar
• Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A. Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther. 2023;40(2):445–459. doi:10.1007/s12325-022-02346-4.
   PubMed Web of Science ®Google Scholar
• Caster O, Aoki Y, Gattepaille LM, Grundmark B. Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf. 2020;43(5):479–487. doi:10.1007/s40264-020-00911-w.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Screening for adverse reactions in EudraVigilance. EMA/849944/2016. 2016:3-33. 2024. https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf.
   Google Scholar
• van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3–10. doi:10.1002/pds.668.
   PubMed Web of Science ®Google Scholar
• Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483–486. doi:10.1002/pds.677.
   PubMed Web of Science ®Google Scholar
• Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–523. doi:10.1002/pds.1001.
   PubMed Web of Science ®Google Scholar
• Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhuang Y, He J. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system. J Immunother Cancer. 2019;7(1):286. doi:10.1186/s40425-019-0754-2.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the use of statistical signal detection methods in the EudraVigilance Data Analysis System. 2024. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/draft-guideline-use-statistical-signal-detection-methods-eudravigilance-data-analysis-system_en.pdf.
   Google Scholar
• Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(6):1469–1485. doi:10.1016/j.cell.2021.02.016.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. CDER drug and biologic approvals for calendar year 2005, Updated through December 31, 2005. https://www.fda.gov/cder/rdmt/InternetNDA05.htm.
   Google Scholar
• France NL, Syed YY. Tirzepatide: a review in type 2 diabetes. Drugs. 2024;84(2):227–238. doi:10.1007/s40265-023-01992-4.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline UK Ltd. Reminder letter regarding the discontinuation of Eperzan (albiglutide). 2018. https://assets.publishing.service.gov.uk/media/5b4c89c5ed915d436ea7ea8b/Eperzan-25062018.pdf.
   Google Scholar
• Kang YM, Jung CH. Cardiovascular effects of glucagon-like peptide-1 receptor agonists. Endocrinol Metab (Seoul). 2016;31(2):258–274. doi:10.3803/EnM.2016.31.2.258.
   PubMedGoogle Scholar
• Triplitt C, Chiquette E. Exenatide: from the Gila monster to the pharmacy. J Am Pharm Assoc (2003). 2006;46(1):44–55. doi:10.1331/154434506775268698.
   PubMed Web of Science ®Google Scholar
• Fineman MS, Mace KF, Diamant M, Darsow T, Cirincione BB, Booker Porter TK, Kinninger LA, Trautmann ME. Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment. Diabetes Obes Metab. 2012;14(6):546–554. doi:10.1111/j.1463-1326.2012.01561.x.
   PubMed Web of Science ®Google Scholar
• Wilson JM, Lin Y, Luo MJ, Considine G, Cox AL, Bowsman LM, Robins DA, Haupt A, Duffin KL, Ruotolo G, et al. The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: a post hoc analysis. Diabetes Obes Metab. 2022;24(1):148–153. doi:10.1111/dom.14553.
   PubMed Web of Science ®Google Scholar
• Mori Y, Matsui T, Hirano T, Yamagishi SI. GIP as a potential therapeutic target for atherosclerotic cardiovascular disease – a systematic review. Int J Mol Sci. 2020;21(4):1509. doi:10.3390/ijms21041509.
   PubMed Web of Science ®Google Scholar